Research Highlight |
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Research Highlight |
Selective JAG1–NOTCH3 targeting shows potential for treating PAH
Different Notch ligands have opposing roles in regulating the proliferation and differentiation of vascular smooth muscle cells in the pulmonary vasculature in pulmonary arterial hypertension. Selectively targeting Jagged 1–NOTCH3 signalling might be an effective and safe strategy for the treatment of this condition.
Dual-therapy stent shows promise
Antibodies against PCSK9—a new era of therapy
Monoclonal antibody therapy lowers LDL-cholesterol levels